Phage Futures Europe 2021

Translating phage-based applications into clinically and commercially viable therapeutics.

VIEW THE 2021 USA AGENDA
Brussels, Belgium
23-24 November, 2021

“Great overview of the field, key players were present, strong opening with focus on patient to orient the audience what matters.”

Dirk Gevers, Global Head, Janssen Human Microbiome Institute, J&J

As a preview ahead of Phage Futures Europe, take a look at highlights from the 2021 Phage Futures USA Congress that took place online in February.

Why Attend

Join us for the return of Phage Futures Europe, this November 2021 in Brussels, as we continue all-important discussions on translating new phage-based applications into clinical studies and beyond. Network and learn from multinational pharma, emerging biotechs, leading academics, investment representatives and regulatory bodies to discover how you can be at the forefront of the developing phage therapy market.

Advisory Board

Author:

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Author:

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Author:

Jessica Sacher

Co-Founder
Phage Directory

Author:

Ruby Lin

Deputy Director of Phage Australia
The Westmead Institute

Author:

Sandra Giannini

Director
GSK

Who Will Be There

5%
Regulatory / Government
5%
Service Provider
15%
Physicians / Clinicians
20%
Biotech
25%
Multinationals
30%
Academics

Regulatory / Government

Service Provider

Physicians / Clinicians

Biotech

Multinationals

Academics

Past attendees

TESTIMONIALS

TALK TO OUR SPEAKERS ABOUT...

1. How to design a successful phage clinical trial

2. How to manipulate the microbiome with phage therapy to treat chronic diseases

3. The implications and safety requirements of administering phage therapy to patients

4. What indications are suitable for phage therapy within Europe?

5. How to obtain broad phage host range and maintain synergy within a fixed cocktail

6. Applications of phage related products as an alternative strategy to access the market 

7. How magistral preparative supports the personalised medicine method

8. The route to appropriate clinical data: through innovative trial design

9. How to alleviate future multi-drug resistance through phage evolution research

10. What are the commercial pathways for phage therapies?

PREVIOUS SPEAKERS INCLUDE

 

Dr Paul Turner

Rachel Carson Professor of Ecology & Evolutionary Biology
Yale University

Dr Paul Turner

Rachel Carson Professor of Ecology & Evolutionary Biology
Yale University

Dr Paul Turner

Rachel Carson Professor of Ecology & Evolutionary Biology
Yale University
 

Dr Benjamin Chan

Research Scientist
Yale University

Dr Benjamin Chan

Research Scientist
Yale University

Dr Benjamin Chan

Research Scientist
Yale University
 

Dr Timothy Lu

Associate Professor of Biological Engineering
Synthetic Biology Center, MIT

Dr Timothy Lu

Associate Professor of Biological Engineering
Synthetic Biology Center, MIT

Dr Timothy Lu

Associate Professor of Biological Engineering
Synthetic Biology Center, MIT
 

Dr David Pride

Associate Director of Microbiology
UC San Diego

Dr David Pride

Associate Director of Microbiology
UC San Diego

Dr David Pride

Associate Director of Microbiology
UC San Diego
 

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic
 

Dr Richard Alm

Director of Alliances
CARB-X / Consultant, WHO

Richard joined CARB-X as an Alliance Director following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company.  He has supported the progression of small molecule compounds from discovery through to late-stage clinical development.  He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he held two post-doctoral positions in the AMR area, one in Australia and one in Canada.

Dr Richard Alm

Director of Alliances
CARB-X / Consultant, WHO

Dr Richard Alm

Director of Alliances
CARB-X / Consultant, WHO

Richard joined CARB-X as an Alliance Director following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company.  He has supported the progression of small molecule compounds from discovery through to late-stage clinical development.  He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he held two post-doctoral positions in the AMR area, one in Australia and one in Canada. Richard is also a consultant on the Global Action Plan on Antimicrobial Resistance for the World Health Organization (WHO).

 

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck
 

Dr Dave Ousterout

CSO & Co-Founder
Locus Bisociences

Dave Ousterout is a co-founder and Chief Scientific Officer for Locus Biosciences. Dave holds a PhD from Duke University where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His expertise is in protein engineering and early stage applications of new technologies to treat human diseases. At Locus, Dave is responsible for development of Locus’s crPhage platform and early stage product development. Prior to Locus, Dave was a consultant at McKinsey & Company.

Dr Dave Ousterout

CSO & Co-Founder
Locus Bisociences

Dr Dave Ousterout

CSO & Co-Founder
Locus Bisociences

Dave Ousterout is a co-founder and Chief Scientific Officer for Locus Biosciences. Dave holds a PhD from Duke University where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His expertise is in protein engineering and early stage applications of new technologies to treat human diseases. At Locus, Dave is responsible for development of Locus’s crPhage platform and early stage product development. Prior to Locus, Dave was a consultant at McKinsey & Company.

 

Dr Cara Fiore

Microbiologist
Center for Biologics Evaluation and Research, FDA

Dr Cara Fiore

Microbiologist
Center for Biologics Evaluation and Research, FDA

Dr Cara Fiore

Microbiologist
Center for Biologics Evaluation and Research, FDA
 

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activi...).

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID’s bacteriophage interest group.  The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.

 

Michael Higgins

Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.

Michael Higgins

Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.

Michael Higgins

Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.
 

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital
 

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center
 

Dr Henry Chambers

MD, Professor of Medicine, Emeritus
University of California

Dr Henry Chambers

MD, Professor of Medicine, Emeritus
University of California

Dr Henry Chambers

MD, Professor of Medicine, Emeritus
University of California
 

Dr Michael Koeris

Portfolio Executive, NIH RADx COVID-19 Response Program
NIH

Dr Michael Koeris

Portfolio Executive, NIH RADx COVID-19 Response Program
NIH

Dr Michael Koeris

Portfolio Executive, NIH RADx COVID-19 Response Program
NIH
 

Dr Mimi Yen

Founder
PhagePro

Dr Mimi Yen

Founder
PhagePro

Dr Mimi Yen

Founder
PhagePro
 

Dr Xavier Duportet

CEO & Co-Founder
Eligo Bioscience

Dr Xavier Duportet

CEO & Co-Founder
Eligo Bioscience

Dr Xavier Duportet

CEO & Co-Founder
Eligo Bioscience
 

Dr Tobi Nagel

Founder & President
Phages for Global Health

Photo Credit: Mark Warren

Dr Tobi Nagel

Founder & President
Phages for Global Health

Dr Tobi Nagel

Founder & President
Phages for Global Health

Photo Credit: Mark Warren

Phages for Global Health is a nonprofit organization that facilitates the application of phages to combat antimicrobial resistance in developing countries. We accomplish this mission in two general ways: by delivering laboratory training workshops through which we teach scientists in developing countries how to isolate and characterize phages locally; and by partnering with developing world researchers to co-develop phage products for specific applications in their countries. Before founding Phages for Global Health, Tobi had 15 years experience in the pharmaceutical industry where she worked with international teams to co-develop products that have been tested in over 80 clinical trials worldwide.

 

Dr Steven Theriault

CEO & CSO
Cytophage Technologies Inc.

Dr Steven Theriault

CEO & CSO
Cytophage Technologies Inc.

Dr Steven Theriault

CEO & CSO
Cytophage Technologies Inc.
 

Dr Frenk Smrekar

CEO & Co-Founder
JAFRAL Ltd

Dr Frenk Smrekar

CEO & Co-Founder
JAFRAL Ltd

Dr Frenk Smrekar

CEO & Co-Founder
JAFRAL Ltd
 

Dr Carrie-Lynn Langlais Furr

CEO & Co-Founder
Bacteriophage & Drug Development Consultants LLC

Dr Carrie-Lynn Langlais Furr

CEO & Co-Founder
Bacteriophage & Drug Development Consultants LLC

Dr Carrie-Lynn Langlais Furr

CEO & Co-Founder
Bacteriophage & Drug Development Consultants LLC
 

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University
 

Dr Jon Iredell

Director Centre for Infectious Diseases & Microbiology
Westmead Institute for Medical Research

Dr Jon Iredell

Director Centre for Infectious Diseases & Microbiology
Westmead Institute for Medical Research

Dr Jon Iredell

Director Centre for Infectious Diseases & Microbiology
Westmead Institute for Medical Research
 

Dr Nick Conley

Principal Scientist
Locus Biosciences

Dr.

Dr Nick Conley

Principal Scientist
Locus Biosciences

Dr Nick Conley

Principal Scientist
Locus Biosciences

Dr. Nick Conley is Principal Scientist for Locus Biosciences.  Before joining Locus in 2018, Nick was co-founder of EpiBiome, a South San Francisco-based precision microbiome engineering company that built the world’s first fully automated high-throughput phage discovery, characterization, and genomics platform, where he served in various roles, including CEO and Chief Science Officer.  During this time, the company gained admission into Illumina Accelerator, Johnson & Johnson Innovation’s JLABS, and Stanford-StartX; secured non-dilutive funding from the Bill & Melinda Gates Foundation and the US Department of Defense; established a top-3 pharma partnership; and raised more than $10 million dollars in financing.  Prior to EpiBiome, Nick was Staff Scientist at HGST, a Western Digital Company.  Nick completed a postdoc in Developmental Biology at Stanford University, and he holds a PhD and BS in Chemistry from Stanford University and The University of Texas at Austin, respectively.

 

 

Anupama Hoey

CBO
Sensei Biotherapeutics

Anupama Hoey

CBO
Sensei Biotherapeutics

Anupama Hoey

CBO
Sensei Biotherapeutics
 

Dr Sailaja Puttagunta

CMO
BiomX

Dr Sailaja Puttagunta

CMO
BiomX

Dr Sailaja Puttagunta

CMO
BiomX
 

Professor Martha Clokie

Professor of Microbiology
University of Leicester

Martha Clokie is Professor of Microbiology at the University of Leicester where she leads a group of post-doctoral researchers and PhD students working on different aspects of therapeutic development of phages that target human and animal pathogens.

Professor Martha Clokie

Professor of Microbiology
University of Leicester

Professor Martha Clokie

Professor of Microbiology
University of Leicester

Martha Clokie is Professor of Microbiology at the University of Leicester where she leads a group of post-doctoral researchers and PhD students working on different aspects of therapeutic development of phages that target human and animal pathogens. Her work encompasses all aspects of phage therapy development – from unravelling fundamental biology to product development, and commercialisation.  She is currently developing phages for major gut pathogens including Clostridial and Salmonella species, for respiratory pathogens and for antibiotic resistant bacteria that cause UTIs.  She is also developing a phage based diagnostic test for Borrelia. Three patents have been filed from her work.

 

Dr Graham Hatfull

Eberly Family Professor of Biotechnology
University of Pittsburgh

Dr Graham Hatfull

Eberly Family Professor of Biotechnology
University of Pittsburgh

Dr Graham Hatfull

Eberly Family Professor of Biotechnology
University of Pittsburgh
 

Dr Bob Blasdel

Research Director
Vesale Pharma

Dr Bob Blasdel

Research Director
Vesale Pharma

Dr Bob Blasdel

Research Director
Vesale Pharma
 

Dr Barbara Hubad

COO
JAFRAL, Ltd

Dr Barbara Hubad

COO
JAFRAL, Ltd

Dr Barbara Hubad

COO
JAFRAL, Ltd
 

Greg Merril

CEO and Founder
Adaptive Phage Therapeutics

Greg Merril

CEO and Founder
Adaptive Phage Therapeutics

Greg Merril

CEO and Founder
Adaptive Phage Therapeutics
 

Dr Subhendu Basu

COO
Adaptive Phage Therapeutics

Dr Subhendu Basu

COO
Adaptive Phage Therapeutics

Dr Subhendu Basu

COO
Adaptive Phage Therapeutics
 

Professor Martha Clokie

Professor of Microbiology
University of Leicester

Martha Clokie is Professor of Microbiology at the University of Leicester where she leads a group of post-doctoral researchers and PhD students working on different aspects of therapeutic development of phages that target human and animal pathogens.

Professor Martha Clokie

Professor of Microbiology
University of Leicester

Professor Martha Clokie

Professor of Microbiology
University of Leicester

Martha Clokie is Professor of Microbiology at the University of Leicester where she leads a group of post-doctoral researchers and PhD students working on different aspects of therapeutic development of phages that target human and animal pathogens. Her work encompasses all aspects of phage therapy development – from unravelling fundamental biology to product development, and commercialisation.  She is currently developing phages for major gut pathogens including Clostridial and Salmonella species, for respiratory pathogens and for antibiotic resistant bacteria that cause UTIs.  She is also developing a phage based diagnostic test for Borrelia. Three patents have been filed from her work.

 

Ella Balasa

Patient Advocacy and Engagement Consultant

Tell me about… your business

Ella Balasa

Patient Advocacy and Engagement Consultant

Ella Balasa

Patient Advocacy and Engagement Consultant

Tell me about… your business

I am a patient advocate, a scientist, a freelance writer, and a person living with cystic fibrosis. Over the past few years, I have become involved in the CF community through serving on research committees, organizing CF virtual events, serving as a director for the US Adult CF Association, and speaking at both local and national levels to raise awareness for CF and shed light to the increasing problem of antibiotic resistance to the CF population. Having a degree in biology, I have worked in an environmental microbiology lab and I've dedicated my work to studying antibiotic resistant organisms and genes from an environmental perspective in surface waters affected by anthropogenic sources. As a patient, I find fascinating the connection between the bacteria that live in the lungs of those affected by CF and the way these same organisms thrive in the environment.

 

Along with an interest in science, I have developed an interest for writing. I have been able to provide a scientific voice and encourage empowerment to the CF community by occasionally writing about my research experiences as well as introspectively writing about the increasing hardship yet countless triumphs that come along with living a life with a chronic disease.

 

Dr Adam Ostrowski

Technical Applications Specialist
Cellexus

Adam is a molecular microbiologist and an applications specialist at Cellexus International Ltd, where he helps customers find the optimal combination of bioreactor solutions offered by Cellexus and achieve the best possible results using our technology. Adam also helps develop new applications and technical solutions for our airlift-mixed single-use bioreactor range and delivers custom requests and improvements requested by our customers.

Dr Adam Ostrowski

Technical Applications Specialist
Cellexus

Dr Adam Ostrowski

Technical Applications Specialist
Cellexus

Adam is a molecular microbiologist and an applications specialist at Cellexus International Ltd, where he helps customers find the optimal combination of bioreactor solutions offered by Cellexus and achieve the best possible results using our technology. Adam also helps develop new applications and technical solutions for our airlift-mixed single-use bioreactor range and delivers custom requests and improvements requested by our customers. Before joining Cellexus, Adam worked in bacteriophage treatment development for plant crop protection and during his academic career has studied Type VI Secretion system and functional proteins in bacterial communities.

 

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments.

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was instrumental in setting up the Global Antibiotic R&D Partnership (GARDP), a foundation that is developing new antibacterial treatments as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and WHO. Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. Prior to joining the Swiss civil service, Peter Beyer worked with the Ecologic Institute in Berlin on environmental law and policy.

 

Josh Hayes

US Regulatory Pathway for Phages as Veterinary Drugs
US FDA, Center for Veterinary Medicine

Josh Hayes

US Regulatory Pathway for Phages as Veterinary Drugs
US FDA, Center for Veterinary Medicine

Josh Hayes

US Regulatory Pathway for Phages as Veterinary Drugs
US FDA, Center for Veterinary Medicine
 

Lorenzo Corsini

Co-Founder and Co-CEO
PhagoMed

Lorenzo is co-founder and co-CEO of PhagoMed, a biotech company developing targeted antimicrobials to treat microbiome-related conditions based on endolysins. From 2008 to 2017, he worked for the Boston Consulting Group. In his latest function as a Principal, he was advising pharmaceutical companies on topics ranging from corporate strategy to efficiency and quality in manufacturing, and leading large teams of consultants across multiple projects. Before, he did his PhD in molecular biology at EMBL Heidelberg. Lorenzo has diploma degrees in biochemistry and business administration.

Lorenzo Corsini

Co-Founder and Co-CEO
PhagoMed

Lorenzo Corsini

Co-Founder and Co-CEO
PhagoMed

Lorenzo is co-founder and co-CEO of PhagoMed, a biotech company developing targeted antimicrobials to treat microbiome-related conditions based on endolysins. From 2008 to 2017, he worked for the Boston Consulting Group. In his latest function as a Principal, he was advising pharmaceutical companies on topics ranging from corporate strategy to efficiency and quality in manufacturing, and leading large teams of consultants across multiple projects. Before, he did his PhD in molecular biology at EMBL Heidelberg. Lorenzo has diploma degrees in biochemistry and business administration.

Previous Event Partners

Lead Media Partner

Become a Partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Agenda Description

We are still working on the 2021 Phage Futures Europe agenda. Please download this year's USA agenda to get a feel for the congress and the typical topics of discussion.

What you can expect from the Europe 2021 congress:

  • 200+ participants from academic, industry, biotech and regulatory bodies onsite
  • European and global phage thought leaders on the speaking agenda and ready to answer your big questions
  • 2 days of furthering phage therapy

Download 2021 USA Agenda

POSTER SESSION

Looking to showcase your recent work to the phage therapy community?

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. 

Poster abstract submission deadline TBC. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

For more information please contact [email protected]



SUBMISSIONS WILL OPEN LATER IN THE YEAR



Resources

Download Resource

Venue

Pullman Brussels Centre Midi, Place Victor Horta 1, 1060 Bruxelles, Belgium

A stay at Pullman Brussels Centre Midi places you in the heart of Brussels, walking distance from Midi Market and Cantillon Brewery. This 4-star hotel is within close proximity of Law Courts of Brussels and Manneken Pis Statue.

Make yourself at home in one of the 237 air-conditioned rooms featuring refrigerators and MP3 docking stations. Wired and wireless Internet access is complimentary, and flat-screen televisions with digital programming provide entertainment. Private bathrooms have deep soaking bathtubs and complimentary toiletries. Conveniences include phones, as well as safes and desks.

Get 10% off your room rate but quoting KISACO RESEARCH at the time of booking.

Click here to reserve your room. 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us